Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy.
Saved in:
| Title: | Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy. |
|---|---|
| Authors: | Xiao P; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Zhao X; Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Wang L; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China., Liu K; Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Li Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China., Zhang M; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Zhang Y; Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Liu Y; Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Feng J; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Hong R; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Fu S; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Zhao H; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Cui J; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Xu H; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Wu X; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Zhang Y; Shanghai YaKe Biotechnology Ltd, Shanghai, China., Wei G; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Chang AH; Shanghai YaKe Biotechnology Ltd, Shanghai, China.; Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China., Zhao K; Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Huang H; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China., Hu Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. 1313016@zju.edu.cn.; Institute of Hematology, Zhejiang University, Hangzhou, China. 1313016@zju.edu.cn.; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China. 1313016@zju.edu.cn. |
| Source: | Bone marrow transplantation [Bone Marrow Transplant] 2026 Mar; Vol. 61 (3), pp. 312-321. Date of Electronic Publication: 2025 Dec 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
